Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleTakeda's integrin inhibitor scores inflammatory bowel disease approvals.AbstractThe article reports on the approval of vedolizumab of Takeda Pharmaceutical Co. Ltd. by the U.S. and European regulators for the treatment of ulcerative colitis and Crohn's disease.SubjectsTAKEDA Pharmaceutical Co. Ltd.; ULCERATIVE colitis; CROHN'S diseasePublicationNature Reviews Drug Discovery, 2014, Vol 13, Issue 7, p485ISSN1474-1776Publication typeArticleDOI10.1038/nrd4388